SNPX
SynaptogenixSNPX
SNPX
About: Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
Employees: 6
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
52% more capital invested
Capital invested by funds: $82.7K [Q4 2024] → $126K (+$43.4K) [Q1 2025]
38% more funds holding
Funds holding: 8 [Q4 2024] → 11 (+3) [Q1 2025]
2.11% more ownership
Funds ownership: 1.73% [Q4 2024] → 3.84% (+2.11%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for SNPX.
Financial journalist opinion
Neutral
PRNewsWire
6 days ago
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token
Singular focus on Bittensor (TAO), the leading AI token by adoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK , June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altucher will lead a TAO-based revenue generation strategy targeting staking yield and token appreciation.
Neutral
PRNewsWire
5 months ago
Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
$19.6 million in cash and cash equivalents as of September 30, 2024 Dramatically reduced cash burn rate expected NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding.
Neutral
PRNewsWire
9 months ago
Synaptogenix Announces $5.0 Million Financing
NEW YORK , Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "Registered Offering") and a concurrent private placement (the "Private Placement" and collectively with the Registered Offering, the "Offering") of additional shares of Preferred Stock and unregistered common stock purchase warrants.
Neutral
PRNewsWire
10 months ago
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in the treatment of neurodegenerative diseases NEW YORK , July 18, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new collaboration agreement with LSU Health New Orleans' Neuroscience Center of Excellence for pre-clinical testing of the Company's polyunsaturated fatty acid (PUFA) analogs as a treatment for spinal cord injury (SCI). The Company also announced that the US Patent and Trademark Office (USPTO) recently issued US Patent No.
Neutral
PRNewsWire
11 months ago
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis
Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , June 26, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS). The fully-funded, open-label clinical trial will be held and managed at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis.
Neutral
PRNewsWire
1 year ago
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery
Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways NEW YORK , May 7, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today applauds the reported move by the U.S. Drug Enforcement Agency (the "DEA") to recommend reclassifying cannabis as a Schedule III drug, and announces potential benefits of the rescheduling to its partner Cannasoul Analytics ("Cannasoul"), founded by the Technion-Israel Institute of Technology, in its discovery of cannabis-based therapeutics. As reported in the press on April 30, 2024, the DEA will move to reclassify cannabis from a Schedule I drug to a Schedule III under the Controlled Substance Act on recommendation by the U.S. Department of Health and Human Services.
Neutral
PRNewsWire
1 year ago
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
NEW YORK , April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market. On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its common stock had failed to meet a closing bid price of $1.00 or more for 30 consecutive business days.
Neutral
PRNewsWire
1 year ago
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
Common stock will begin trading on split-adjusted basis on April 5, 2024 NEW YORK , April 3, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. The reverse stock split will become effective at 5:00 p.m.
Neutral
PRNewsWire
1 year ago
Synaptogenix President Daniel L. Alkon, M.D.
Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D.
Neutral
PRNewsWire
1 year ago
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe Alzheimer's disease (AD) patients NEW YORK , Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders.
Charts implemented using Lightweight Charts™